2m 2m 2m 2m 2m 2m 2m
UROGEN PHARMA (URGN)
NASDAQ
$25.03-$1.07 (-4.09%)
Price as of Nov 12, 2026 10:20 AM EST- $1.2BMarket Cap
- 3.82%1-Year Change
- BiotechnologyIndustry
UROGEN PHARMA (URGN)
$25.03-$1.07 (-4.09%)
URGN | vs History | vs S&P 500 | |
|---|---|---|---|
General Statistics | |||
Latest Close | $26.10 | ||
Change | +$0.78 (+3.08%) | ||
Open | $25.56 | ||
High | $26.24 | ||
Low | $25.40 | ||
Previous Close | $25.32 | ||
Volume | 818,221 | ||
30-Day Average Volume | 1,202,518 | ||
1-Week Change | -9.19% | ||
1-Month Change | -29.13% | ||
1-Year Change | 3.82% | ||
3-Year Change | 127.75% | ||
5-Year Change | 38.76% | ||
Fundamentals | |||
Shares Outstanding | 46.8M | ||
Total Assets | $271.9M | ||
Market Cap | $1.2B | ||
Enterprise Value | $1.3B | ||
Period: QTR TTM FY | |||
Revenue | $89.0M | ||
Net Income | -$1.5M | ||
Free Cash Flow | -$15.3M | ||
EBIT | -$446,000.00 | ||
EBITDA | -$365,000.00 | ||
Net Working Capital | $177.9M | ||
EPS | -$0.03 | ||
Enterprise Value/EBITDA | -3,632 | ||
Enterprise Value/Revenue | 15 | ||
P/B | -10 | ||
P/E | -870 | ||
PEG | -10 | ||
Price/Free Cash Flow | -80 | ||
Price/Operating Cash Flow | -80 | ||
Dividends & Splits | |||
Forward Annual Dividend Yield | N/A | ||
Trailing Annual Dividend Yield | N/A | ||
Ex-Dividend Date | N/A | ||
Last Split Factor | N/A | ||
Last Split Date | N/A | ||
Earnings & Revenue